North Carolina is currently home to 2623 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
NCT06712823
Recruiting
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Gender:
ALL
Ages:
16 years and above
Trial Updated:
11/27/2024
Locations: Crinetics Study Site, Morehead City, North Carolina
Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Register for Updates
A Clinical Trial of STP0404 in Adults with HIV-1 Infection
NCT05869643
Recruiting
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/27/2024
Locations: Atrium Health Wake Forest Baptist Medical Center - PPDS, Winston-Salem, North Carolina
Conditions: HIV-1-infection
Register for Updates
Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
NCT05835466
Recruiting
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Register for Updates
Pilot Testing of an Equity Focused and Trauma-informed Communication Intervention During Family-centered Rounds
NCT05618652
Recruiting
Development and pilot testing of a clinician coaching communication intervention to improve communication between medical teams and caregivers (parents, family members) of children in the hospital. Our team is specifically focused on improving partnership, respect, and collaboration with Black and Latinx caregivers of children in the hospital by incorporating elements from trauma-informed care and racial equity into a communication intervention. The investigators will explore the impact of this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Duke University Health Sustem, Durham, North Carolina
Conditions: Hospitalism in Children, Post Traumatic Stress Disorder
Register for Updates
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Western Carolina Retinal Associates, Asheville, North Carolina
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators
NCT06333067
Recruiting
Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation.
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
11/26/2024
Locations: Skin Wellness Dermatology Associates, Durham, North Carolina
Conditions: Lax Skin
Register for Updates
Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors
NCT06150183
Recruiting
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone and when it is used together with another antibody cancer drug (pembrolizumab) in patients with different types of cancer. Patients will receive either BNT314 alone or BNT314 combined with pembrolizumab. Phase 1 of the study consists of a dose escalation part, and a safety run-in (SRI) and expansion part: Dose escalation: In this part of the study, patients will be assigned to multiple dose levels (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Carolina BioOncology Institute, LLC, Huntersville, North Carolina
Conditions: Advanced Malignant Solid Tumor
Register for Updates
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD
NCT05936970
Recruiting
The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
Register for Updates
Preschool Attention and Sleep Support (PASS)
NCT05862727
Recruiting
This study will be investigating two telehealth interventions for preschoolers with ADHD. The study is divided into two Aims. During Aim 1, caregivers of preschoolers with attention concerns, pediatric behavioral health professionals, and pediatric primary care providers will take part in two virtual focus groups to provide their perspective on ways to improve the telehealth intervention being evaluated.
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
11/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: ADHD, Psychiatric Health
Register for Updates
Tourette Discrimination (TD) Stigma Scale
NCT05696769
Recruiting
The goal of this qualitative study is to understand the challenges of stigmatization and discrimination in children and young adults with Chronic Tic Disorders (CTD), including Tourette Syndrome. Measuring and understanding how stigma affects those with CTD will help inform future work.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
11/26/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence, Tic Disorder, Childhood, Tics
Register for Updates
Daratumumab in Primary Antiphospholipid Syndrome
NCT05671757
Recruiting
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab acc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: Duke University, Durham, North Carolina
Conditions: Autoimmune Disorders
Register for Updates
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Advanced Cancer
Register for Updates